Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Changes include new information about risks associated with dolutegravir during pregnancy and removal of older drugs owing to toxicities.
Dovato (dolutegravir/lamivudine) is the second approved two-antiretroviral regimen.
Researchers argue that among children born to mothers with HIV, other factors such as the virus and substance use prompt such outcomes.
A speedy overview of the major scientific findings presented at the International AIDS Conference in Amsterdam (AIDS 2018)
A large ongoing study in Botswana has found that about 1 in 150 babies exposed to Tivicay at conception developed such birth defects.
A recent study compared birth outcomes among HIV-positive women exposed to various antiretroviral regimens.
The integrase inhibitor is included in the single-tablet HIV regimens Triumeq and Juluca.
Pregnant women who take antiretrovirals (ARVs) to treat HIV early in their pregnancies appear to have a low risk of birth defects in their inf...
There were no HIV transmissions and few birth defects in the babies of HIV-positive African women who were treated with ARV therapy.
Screening for fetal abnormalities is accurate for pregnant women living with HIV and should be offered
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.